Nezer Belen
Family · Chula Vista, CANPI 1386120723
Payments from drug & device makers
Across 475 payments — averaging $44.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Boston Scientific$5K
- Edwards Lifesciences$3K
- Heartflow, Inc.$1K
- AOP Health US, LLC$1K
- Johnson & Johnson$702
- plus $4K from 32 others
What the payments were for
- Travel & lodging$6633%
- Food & beverage$20,12696%
- Education$1831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 179 | $5,799 |
| Boston Scientific | 76 | $5,031 |
| Edwards Lifesciences | 23 | $2,514 |
| Heartflow, Inc. | 13 | $1,434 |
| AOP Health US, LLC | 2 | $1,075 |
| Johnson & Johnson | 26 | $702 |
| Shockwave Medical, Inc | 7 | $533 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $523 |
| Impulse Dynamics (USA) Inc. | 10 | $490 |
| Medtronic | 12 | $373 |
| Biotronik Inc. | 5 | $262 |
| Pfizer | 14 | $245 |
| Novo Nordisk | 7 | $231 |
| Merck | 9 | $207 |
| E.r. Squibb & Sons, L.L.C. | 9 | $153 |
| Astellas Pharma US Inc | 3 | $121 |
| Esperion Therapeutics, Inc. | 7 | $117 |
| Amgen | 7 | $114 |
| Biosense Webster, Inc. | 2 | $114 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $111 |
| Kestra Medical Technology Services, Inc. | 3 | $110 |
| Boehringer Ingelheim | 6 | $105 |
| GSK | 1 | $95 |
| Cleerly, Inc. | 1 | $83 |
| Cvrx, Inc. | 5 | $83 |
| Daiichi Sankyo Inc. | 3 | $62 |
| AstraZeneca | 3 | $42 |
| Scpharmaceuticals Inc. | 1 | $39 |
| Atricure, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Abiomed | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Novartis | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$2,150
- SAPIEN 3 Ultra RESILIA$1,414
- FFRct$1,222
- WATCHMAN FLX$1,024
- AVEIR$788
- Confirm Rx$744
- Watchman$727
- WATCHMAN Access System$636
- OPTIMIZER$503
- MitraClip$436
- CardioMEMS HF System$387
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$380
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$319
- Farapulse$277
- VersaCross Access Solution$257
- XARELTO$250
- LUX-Dx Insertable Cardiac Monitor$150
- Quadra Assura CRT Defibrillator$149
- CARDIOMEMS$128
- Vascular Lithotripsy$125
How this compares
$20,972 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 76 | $86,236 |
| EliquisApixaban | 35 | $53,871 |
| FarxigaDapagliflozin Propanediol | 17 | $26,343 |
| EntrestoSacubitril/Valsartan | 13 | $20,568 |
| Ranolazine ErRanolazine | 24 | $3,169 |
| Atorvastatin Calcium | 198 | $2,526 |
| Amlodipine Besylate | 203 | $1,816 |
| Metoprolol Succinate | 114 | $1,414 |
| Losartan Potassium | 140 | $1,308 |
| Ezetimibe | 25 | $759 |
| Rosuvastatin Calcium | 21 | $750 |
| Carvedilol | 84 | $630 |
| Lisinopril | 53 | $593 |
| Chlorthalidone | 27 | $487 |
| Hydralazine Hcl | 46 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $702 | $86,23676 claims |
| PfizerEliquis | $245 | $53,87135 claims |
| AstraZenecaFarxiga | $42 | $26,34317 claims |
| NovartisEntresto | $15 | $20,56813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Chula Vista
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.